subscribe
 

Heparan sulphate antibodies

26th September 2016

Posted By Paul Boughton


AMSBIO has produced a new 24-page guide that brings together applications, protocols, results and citations to provide an informative resource for researchers using heparan sulphate antibodies.

Heparan Sulphate (HS) is synthesised as the glycosaminoglycan (GAG) component of heparan sulphate proteoglycans (HSPGs). It is expressed on the cell surface of virtually all cell types and basement membranes. It displays specific interactions with many biologically active proteins and, thus is involved in many important biological processes. Many researchers are interested in examining the dynamic distribution of HSPG in tissues and also analysing HS structures to elucidate the biological functions of HSPG. The non-immunogenic character of HS makes this type of antibody difficult to raise, so the few hybridoma-derived mouse anti-HS antibodies such as JM403, 10E4 and 3G10 are valuable tools for HS research. Using multiple HS antibodies that recognise subtle differences in HS patterning can be useful in applications such as flow cytometry allowing multiple cell types to be directly compared.

AMSBIO offers a suite of high quality heparan sulphate antibodies from the important clones F69-3G10, F58-10E4 and JM403. These antibodies are ideal for targeted binding of HS for HSPG research and provide a range of anti-HS antibodies recognizing distinct HS substructures, which have been well-characterised in previous studies.

The guide provides an informative introduction to applications of JM403, 10E4 and 3G10 Heparan Sulphate antibodies; including use of the 10E4 and JM-403 clones together in ELISA to detect or measure HS. GAGs are not species-specific, so in common with AMSBIO’s other GAG antibodies, the clones featured in this guide react across a wide range of species. 





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe